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Immune-mediated bone marrow failure 
syndromes and cytopenias
Pathophysiology of immune mediated bone 
marrow failure 
Idiopathic aplastic anemia (AA) can serve as a proto-
type of immune-mediated bone marrow failure syn-
dromes but similar pathophysiologic mechanisms may
also operate in related diseases such as paroxysmal
nocturnal hemoglobinuria (PNH) or some forms of
myelodysplastic syndrome (MDS). Most often these
disease are characterized by global cytopenia. Howev-
er, some single-lineage cytopenias such as immune-
mediated pure red cell aplasia, amegakaryocytic
thrombocytopenic purpura as well as certain forms of
autoimmune neutropenias and white cell aplasia may
be mediated by the cellular immune system. The best
example of lineage-restricted cytopenias are those that
accompany T cell large granular lymphocyte leukemia
(T-LGL) which frequently presents with various
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Abstract: The unique structure of the T cell receptor (TCR) enables molecular identification of individual T cell clones and
provides an unique opportunity for the design of molecular diagnostic tests based on the structure of the rearranged TCR
chain e.g., using the TCR CDR3 region. Initially, clonal T cell malignancies, including T cell large granular lymphocyte
leukemia (T-LGL), mucosis fungoides and peripheral T cell lymphoma were targets for the TCR-based analytic assays such
as detection of clonality by T-γ rearrangement using γ-chain-specific PCR or Southern Blotting. Study of these disorders
facilitated further analytic concepts and application of rational methods of TCR analysis to investigations of polyclonal T
cell-mediated diseases. In hematology, such conditions include graft versus host disease (GvHD) and immune-mediated
bone marrow failure syndromes. In aplastic anemia (AA), myelodysplastic syndrome (MDS) or paroxysmal nocturnal
hemoglobinuria (PNH), cytotoxic T cell responses may be directed against certain antigens located on stem or more line-
age-restricted progenitor cells in single lineage cytopenias. The nature of the antigenic targets driving polyclonal CTL
responses remains unclear. Novel methods of TCR repertoire analysis, include VB flow cytometry, peptide-specific tetramer
staining, in vitro stimulation assays and TCR CDR3-specific PCR. Such PCR assay can be either VB family-specific or mul-
tiplexed for all VB families. Amplified products can be characterized and quantitated to facilitate detection of the most
immunodominant clonotypes. Such clonotypes may serve as markers for the global polyclonal T cell response. Identifica-
tion of these clonotypes can be performed in blood and tissue biopsy material by various methods. Once immunodominant
clonotypes corresponding to pathogenic CTL clones are identified they can serve as surrogate markers for the activity of the
pathophysiologic process or even indicate the presence of specific antigens. The relevance of the individual clonotypes can
be ascertained from clinical correlations with the activity of the disease. Quantitative clonotypic assays such as sequencing
of multiple CDR3 clones or clonotypic Taqman PCR can be applied for the monitoring of the immunosuppressive therapy
and prediction of relapse. Future technologies may allow for the design of clonotypic microarrays or other more clinically
applicable methods of clonotypic diagnostics. Similarly, identification of immunodominant clonotypes may facilitate tar-
geting of autoimmune or malignant clones with vaccination and induction of anti-idiotypic responses. 
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Review article
Various lines of laboratory evidence point towards
an immune-mediated inhibition of hematopoiesis at
specific differentiation stages, but the efficacy of
immune-suppressive strategies targeting T cells pro-
vides the strongest argument for the involvement of T
cells in the pathophysiology of AA and some other
bone marrow failure syndromes. Clearly, some forms
of immune cytopenias such as those seen with lupus
erythematosus, and autoimmune neutropenia, are
mediated by antibodies likely directed against
hematopoietic progenitor or more mature cells. Theo-
retically, even if T cells are mostly responsible for the
damage to the progenitor and stem cell compartment,
one could speculate that the cellular immune response
will be accompanied by a corresponding antibody
response. However, serologic markers for most com-
mon types of immune-mediated bone marrow failure
syndromes are missing and B cell targeting strategies
such as Rituximab have not been applied to the thera-
py of these disorders. Similarly, attemepts of antigen
identification have not yielded clinically utilizable
autoantibodies. 
Modes of inhibition 
Effector mechanisms in hematopoietic inhibition may
involve various pathways, including release of
inhibitory cytokines leading to apoptosis of
hematopoietic progenitor and stem cells. The speci-
ficity of such a mechanism may be difficult to recon-
cile with a sometimes very narrow spectrum of
hematopoietic inhibition as seen single lineage cytope-
nias. Direct perforin/granzyme-mediated killing by
cytotoxic effector cells may be another mechanism by
which specific targeting of stem cells or progenitors
can be explained. Clearly, the distribution of target
antigens may determine the killing spectrum. Terminal
CTL are likely the most efficient effector cells and so
far there is little evidence that the hematopoietic inhi-
bition in the most common forms of bone marrow fail-
ure is mediated by natural killer cells. It is possible that
a CTL population lacking CD28 and expressing CD57
contains most of the pathogenic clones and can serve
as a source of T cells for molecular TCR analysis. 
Cellular targets 
Immune elimination of stem cells due to the presence
of a cross-reactive antigen or autoantigen restricted to
the stem cell compartment may be responsible for AA
(Fig. 1). In MDS, various possible mechanisms have
been postulated to explain the occurrence of cytopenia
due to inhibition of normal residual hematopoiesis. For
example, the immune attack can be part of physiolog-
ic anti-tumor surveillance response to abnormal and/or
dysplastic cells in the bone marrow. In such a situation,
the immune attack may not be sufficiently specific and
results in collateral damage with inhibition of normal
hematopoiesis. Conversely, the initial immune attack
may be directed against normal stem cells as in AA,
resulting in selection pressure and outgrowth and
escape mutant hematopoietic clones. Similar consider-
ations apply to the evolution of glycophosphatidy
l-deficient clones in PNH [55]. 
Target antigens and methods of their detection 
Even if the damage to the hematopoietic progenitor
and stem cells is mediated by the cellular immune sys-
tem, the pathogenic process could elicit antibody
responses. Specific target antigens have been
described for Felty's syndrome associated with neu-
tropenia [10], and AA [12,19]. Despite these reports,
clinically relevant tests have not been introduced. The
nature of the identified antigens does not reveal clues
as to the restriction of the immune attack to the
hematopoietic tissues as the described target antigens
appear to be expressed in various tissues. 
Clinical observations may provide some clues as to
the distribution of the target antigens. It is very likely
that in AA the target antigen is located on hematopoi-
etic stem cells, while in the lineage-restricted cytope-
nias antigens expressed on specific progenitors are
likely to be targets. This restriction may be particular-
ly obvious in some cases of LGL leukemia associated
with either neutropenia or pure red cell aplasia (Fig. 1).
Similar conclusions can also be drawn with regard to
the tropism of putative viral agents implicated in the
pathogenesis of bone marrow failure syndromes. Even
if an initial specific "inciting" antigen does exist, it is
likely that the later immune response can be character-
ized by the responses directed against multiple anti-
gens in concordance with the antigenic spread theory. 
Molecular methods of T cell receptor analysis
A lack of knowledge of the offending antigens frus-
trated generations of investigators studying bone mar-
row failure states. Alternative strategies to investigate
T cell responses in AA and other related diseases have
been developed. One such method, molecular analysis
of clonal T cell repertoire, is aimed at identification of
immunodominant marker clones and allows for the
study of the kinetics of the cellular immune response
without knowledge of specific antigens [42]. The basis
for this principle has been established during investi-
gations of clonal T cell lymphoproliferations. As
applied to polyclonal T cell-mediated processes, it has
been hypothesized that immunodominant clones do
exist and such clones can serve as markers of anti-
geneic processes irrespective of their recognition spec-
trum. Due its unique and highly specific structure, the
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rearranged portion of the variable B-chain (VB), the
CDR3 region, can serve as a molecular signature of
individual clones and their frequency can be easily
established. 
Analysis of TCR rearrangement is routinely
applied to detect clonality for the diagnosis of lym-
phoid malignancies. However, molecular analysis of
TCR can be a powerful tool in the study of T cell
responses to pathogens and in autoimmune diseases
[42]. The concept of oligoclonality in the context of
the immune response is based on the presence of
immunodominant T cell clones and has to be viewed in
relation to the T cell population used for analysis. Dur-
ing immune reactions, a limited number of clones usu-
ally undergoes expansion triggered by foreign agents.
The derailment of immune regulation allows for the
expansion of T cell clones specific for "self", resulting
in an autoimmune disease (Fig. 2). In hematology,
LGL leukemia is suggestive of an exaggerated clonal
response to a specific hematopoietic antigenic target
and illustrates that an extreme expansion of a single
clone can lead to a specific CTL-mediated pathology.
Normally, clonal TCR rearrangement cannot be detect-
ed in unseparated blood or marrow by traditional
methods. However, individual T cell clones can signif-
icantly expand, and certain T cell subpopulations
(defined e.g., by a specific VB chain usage or specific
phenotypic markers), may demonstrate molecular
oligoclonality. Expanded T cell clones may represent
immunodominant responses, which can be studied by
various molecular methods. In the laboratory, analysis
of the individual TCR VB-chain representation, CDR3
amplification product size fragment skewing and
determination of the frequency of individual clonotyp-
ic sequences were developed [42]. Such molecular
analysis of TCR has been employed in the investiga-
tion of classical autoimmune diseases [5,9,15,20-22,
38,32,36] and T cell lymphoproliferative disor-
ders[29-31].
The techniques used to study T cell clonality are
based on the extraordinary biology of the TCR. The
TCR is a heterodimer comprising of α (A) and β (B)
chains,  both encoded by rearranged V (D) J segments
and a constant region (for review see [1,2,13,16,40].
This rearrangement between V, D and J regions
accounts for the heterogeneity and fine specificity of
antigen recognition and is mostly carried by the VB
CDR3 domain. The CDR3 of the TCR VB chain is a
non-germ line-encoded hypervariable region directly
related to T cell recognition of peptides in the appro-
priate HLA context. During the recombination
process, transferases add or remove nucleotides at var-
ious VB-DB or DB-JB junctions, leading to 6-8 amino
acid differences between CDR3 regions within each
VB chain, thus creating unique signature sequences.
This process accounts for the virtually unlimited anti-
gen-driven expansion of specific clones. As the CDR3
region appears to be responsible for the recognition of
peptides presented in the context of HLA, while CDR1
and 2 regions exhibit affinity to a specific HLA type,
similar CDR3 sequences that recognize a specific anti-
gen may possibly be found in individuals with differ-
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Fig. 1. Immune-mediated bone marrow failure, targets and effector cells.
ent HLA types [1]. Despite HLA-restriction, CDR3
regions derived from different VB families may show
similar sequences if the CTL clones recognize identi-
cal antigens. 
Although most of the natural immune responses
may be polyclonal, acutely significant oligoclonal
expansions may occur. For example, in acute infection
with cytomegalovirus or Epstein-Barr virus, very high
frequencies of virus-specific T cells have been
observed [14,28,41]. An increase in the size of the
entire VB family can be detected by flow cytometry
[25] or by reverse hybridization techniques [34]. LGL
leukemia represents an extreme clonal expansion that
results in an increase in the size of an entire VB family.
Analytic strategies 
The VB chain, due to its recombinatorial and junction-
al diversity, is more suitable for identification of
unique clonotypic markers for T cell clones. Clonal or
oligoclonal T cell expansions will result in skewing of
the otherwise normal Gaussian size distribution of
recombined CDR3 amplification products [13,16,37,
40] that is amenable to molecular analysis by size
measurement of CDR3 amplification PCR products
(CDR3 spectratyping). Analysis of the VB repertoire
has been called VB spectratyping. An increased fre-
quency of individual clones can also be detected by
cloning CDR3 amplification products and sequencing
individual clones. Under normal circumstances, due to
the great variability of the CDR3 region within each
VB family, most of the cloned sequences will be
unique. However, expansion of specific T cells will
result in a higher probability of their amplification and
cloning and consequently, many cloned CDR3 regions
will be identical. The frequency of homologous CDR3
sequences corresponds to the degree of clonal over-
expansion, and in LGL leukemia only identical, clonal
sequences are usually obtained. The sequencing
method is very labor-intense. Similar to spectratyping,
it requires PCR amplification of each individual VB
family, sub-cloning and sequencing of many individ-
ual clones followed by sequence analysis and calcula-
tion of the clonal frequency. Flow cytometry may be
used to narrow the choice of VB families for analysis
as immunodominant clonal expansions may result in
relative increase in entire VB family (Fig. 3). 
Recently a new multiplexed VB PCR assay has
been introduced allowing for the amplification of the
entire VB spectrum just in a few PCR reaction. Simi-
lar to individual VB PCR assay, the products of such
PCR reaction can be sub-cloned and sequenced. This
technique may be used upfront to determine most pre-
dominant clonotypes and subsequently their frequency
within the given VB family can be determined using
individual VB PCR. Such an approach leads to a high-
er level of detection of immunodominant expansions
(Fig. 3) [39,51,52]. Following identification of poten-
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Fig. 2. Clonality of the CTL responses in bone marrow failure.
tially pathogenic clonotypes, clonotypic sequences can
be used for the design of specific assay to determine
frequency of individual clones in blood or tissues.
Techniques available include clonotypic PCR and
clonotypic Taqman PCR allowing for the determina-
tion of clonal frequencies (Fig. 4). 
Molecular techniques can be applied not only to the
detection of expanded T cell clones in blood but also
in tissues affected by immune processes such as mar-
row and gut, liver or skin biopsies. In addition, paraf-
fin-embedded tissues can be used as a source of
nucleic acid for molecular TCR utilization analysis
[3,51,52].
TCR analysis in LGL leukemia and lessons for
other bone marrow failure syndromes 
In many important aspects the clonal CTL expansions
seen in LGL can be used as a simple model of CTL
responses seen in other polyclonal CTL-mediated dis-
eases. The investigative principles established in this
disease allow for better application of molecular TCR
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Fig. 3. Methods of molecular TCR analysis.
analyses in a more complex processes. Similar to idio-
pathic AA, in which immune-mediated destruction of
hematopoiesis has been inferred from the success of
immunosuppressive therapies [52,53], LGL has been
shown to respond to immunosuppression [4,7,48,49].
LGL leukemia can occur in the context of MDS and
PNH [23,35,43,49,52], and in this setting it may repre-
sent an aberrant immune response to the genetically
altered dysplastic cells. A pathophysiologic relation-
ship between these immune-mediated bone marrow
failure states suggests that molecular analysis of TCR
repertoire can be applied to study of not only AA and
PNH but also MDS. For example, MDS often evolves
from AA, and hypoplastic MDS shows many clinical
similarities to AA [17,50]. 
Flow cytometric [31] and molecular [8] VB typing
have previously been applied to large cohorts of LGL
patients. LGL-associated or LGL-like clonal expan-
sions were described on molecular level in several
smaller series, including patients with Felty's syn-
drome[6], MDS and erythroid hypoplasia [35] and
patients with rheumatoid arthritis [18]. Flow cyto-
metric detection of phenotypically abnormal CTL
populations and VB CDR3 genotyping may leave a
significant number of CTL proliferations unidenti-
fied. Complete molecular analysis of a large cohorts
of LGL patients has been recently reported [38,52].
By refining these methods and sequencing of expand-
ed clones a much higher detection level can be
achieved. 
In general, analysis of clonal utilization patterns in
LGL is based on the theory that the unique and often
very lineage restricted cytopenias associated with LGL
leukemia may be a result of the lineage specificity of
the target antigens recognized by clonal TCR (Fig. 1).
Consequently it may be possible that in patients with
similar presentations and matching HLA-restriction
elements, identical or highly homologous clonotypes
will be found. Clearly, given the estimated physiolog-
ic variability of CDR3 regions within the VB chain [2],
such an event that may be rare but it would prove the
nonrandom origin of clonal transformation in LGL
leukemia. By studying a relative large number of
patients with LGL, identical expanded clonotypes
were found in 2 patients. CTL clones identified in LGL
associated with neutropenia may indicate an autoim-
mune process modified by e.g. mutational event may
result in extreme clonal polarity. Based on the diversi-
ty of the physiologic TCR repertoire and the extreme-
ly low frequency of shared clonotypes identified
between healthy controls, the coincidental finding of
common clonotypes is unlikely. It strongly suggests
that these clones do not evolve randomly, but occur in
the context of an initially polyclonal immune response
directed against identical or highly similar antigenic
targets. This conclusion is further supported by the
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Fig. 4. Quantitation of clonotypes. Clinical application of clonotypic diagnostics.
identification of sequence sharing between the two
other immunodominant clonotypes identified in
patients and non-expanded clonotypes found in other
LGL cases. It is likely that these minor clonotypes are
the remnants of an initial polyclonal response. The low
frequency of these clones may be due to "dilution" by
the expanding semiautonomous LGL clones. Detec-
tion of high levels of similarity between clonotypes
(including both minor and immunodominant clono-
types) within a given VB repertoire of individual
patients also supports our conclusions that several
clones recognizing similar or identical peptides may
be present prior to the expansion of immunodominant
clones. The occasional presence of distinct clonotypes
that are identical in their amino acid sequences but dis-
tinct in their nucleotide sequences may have resulted
from selection of individual clones with identical anti-
genic affinity. In such cases the effective frequency of
the corresponding TCR may be a sum of two inde-
pendently rearranged clones.
Very analogous results to those obtained in LGL
leukemia have been reported in a small cohort of intri-
cately characterized PNH patients [47]. It is likely that
clinically-manifested cases of LGL leukemia represent
the extreme clonal/oligoclonal T cell lymphoprolifera-
tions that, to a lesser extent, may also be present in cer-
tain patients with otherwise unexplained cytopenias in
which clonal expansion may not be detected with tra-
ditional laboratory tools. We hypothesized that high
resolution T cell receptor repertoire analysis may
uncover clonal cytotoxic T cell expansions that are
quantitatively less pronounced than those seen in LGL
but are pathophysiologicaly analogous and can serve
as markers for T cell-mediated autoimmune process.
We have recently studied 20 patients with unexplained
neutropenia and found expanded CTL clones in a large
proportion of these patients. In comparison to LGL
leukemia, CTL clones found in some cases of idio-
pathic neutropenia were less dominant but clearly dis-
tinguishable from marginally expanded clonotypes
found occasionally in healthy individuals. 
Aplastic anemia, paroxysmal nocturnal 
hemoglobinuria, myelodysplastic syndromes
Even in LGL leukemia not all cases will show clonal-
ity using TCR rearrangement analysis, but clearly the
results of this test depend on the proportion of mono-
clonal cells in circulation. In classical immune-mediat-
ed bone marrow failure syndromes, polyclonality pre-
cludes positive TCR rearrangement studies. However,
clonal expansions, in some cases very substantial, have
been described in AA, PNH and MDS. When VB CDR3
repertoire analysis (CDR3 spectratyping) has been per-
formed in patients with AA [27,44-46,56,57], PNH [23,
35,43,47] and MDS [11,26,35,52], some studies showed
a broadly normal VB distribution pattern with over-
expression of a few VB types, indicative of selective
CDR3 usage. However, skewing was not limited to spe-
cific VB families, likely due to lack of selection of
patients based on their HLA type. As expected in the
absence of malignant lymphoproliferation, when 
J-regions were analyzed monoclonality was excluded
[33]. These studies demonstrated that despite their com-
plexity in AA and MDS, polyclonal CTL responses can
be successfully detected and characterized.
When we have used flow cytometry to study VB
family skewing as a surrogate for more stringent
molecular clonal analysis, we were able to detect VB
expansions within the CTL population,  there was no
difference in the average size or frequency of clonal
expansions in AA and MDS nor was the hypocellularity
(irrespective of the diagnosis) associated with more pro-
nounced VB skewing. Genotyping of the CDR3 region
demonstrated oligoclonality in around a majority of
these expanded VB families. Even by this rather crude
analysis a continuum of responses was observed from
multiple VB families expanded in AA and MDS to
extreme monoclonal expansions in typical LGL [52].
In MDS, an extensive skewing of the CDR3 region
showed normalization after immunosuppressive thera-
py [26]. In another report, specific CTL clones were
defined based on their VB and VA utilization pattern in
four patients with refractory anemia. Interestingly,
clinical description of the cases implies that in 3 of
these RA patients an LGL clone was present, consis-
tent with a coexisting LGL leukemia [35]. For exam-
ple, while immune response in AA, MDS and PNH
may be less polarized, expansions of entire VB-fami-
lies and oligoclonal skewing of the TCR VB CDR3
have been observed. 
Recently, we conducted a systematic analysis of the
TCR repertoire in patients with MDS and AA [52].
This study focused on the development of efficient and
precise tools of clonotypic diagnosis in MDS and AA
rather than on the functional characterization of
immunodominant clonotypes. When we applied the
previously used VB CDR3 PCR of expanded VB fam-
ilies as well as multiplex CDR3 PCR to generate
clonotypic amplicons for analysis of the frequency of
amplified clonotypes. In agreement with previous
reports involving smaller groups of MDS patients [26,
35,52], we found evidence for oligoclonal T cell-medi-
ated immune responses not only in AA but also in
MDS patients. The newest technologies allow for
detection and characterization of immundominant
clonotypes not only in freshly isolated blood and bone
marrow but also in historical archived paraffin-embed-
ded specimens. The multiplex PCR assay proved a
very efficient means of identification of the most
expanded clonotypes. Following multiplex PCR, VB-
specific amplification using VB primers was per-
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formed with primers allowing for the amplification of
VB family corresponding to the redundant clone
detected in the multiplex PCR. This approach allowed
for quantitation of clonal expansion within VB family.
Such a rational method led to identification of oligo-
clonally-expanded clones even when VB flow cytom-
etry was not possible (biopsy material) or not inform-
ative. Previously this method was applied to the analy-
sis of LGL leukemia [39,51] and now has been adopt-
ed to study MDS and AA [52]. 
The size of expanded clones identified in our study
in MDS and AA patients was comparable, ranging
from 33-100% of a given VB family. This finding has
to be viewed in the context of physiologic variability
of the TCR, which was previously estimated from a
large number of control sequences derived from
healthy individuals [52]. Interestingly, the MDS
patient group included 3 patients in whom traditional
flow cytometric assays detected LGL T cell clones and
confirmed a diagnosis of concomitant LGL. Interest-
ingly, using our strategy, LGL-like expansions of VB
families (>30% of total CD8+ cells) were found in
additional MDS patients, suggesting that LGL-like,
subclinical clonal CTL responses may be more fre-
quently encountered than can it can be extrapolated
based on traditional clinical testing. Subsequent stud-
ies of T cell γ rearrangement confirmed the presence of
oligoclonality in these patients. Molecular assays with
TCR analysis could be useful to further refine the diag-
nostic criteria for some MDS patients who share over-
lapping features with LGL leukemia patients not
detectable by routine techniques. In addition, to the
sensitive detection of clonal dominance in blood, iden-
tification of oligoclonality in biopsy specimens is very
instructive and would be difficult to reconcile with the
argument that expanded clones are due to infection or
alloimmunization. 
In general, immunodominant CTL clonotypes can
be detected at comparable rates in AA and MDS irre-
spective of the morphologic subtype. Immunodomi-
nant clones derived from blood or bone marrow can be
used as markers of the activity of the disease, assum-
ing that they are related to the pathogenic process
rather than to infections or alloimmunization. The dis-
ease-specificity of the clonotypes detected in our stud-
ies was supported by the correlation of their frequency
with hematologic response to immunosuppression
[47,52]. Similarly, isolation of immunodominant
clonotypes in bone marrow biopsy specimens as well
as in blood of patients at presentation indirectly sup-
port the notion of specificity [3,51,52]. 
Immunodominant clonotypes can have diagnostic
utility independent of their (unknown) specificity.
Using quantitative sequencing methods, a correlation
between the level of some but not all clonotypes and
activity of AA has been demonstrated [46]. Clearly, the
most stringent proof would be provided by functional
analysis but such an analysis was not possible due to
the lack of putative antigens needed for the assays. Of
note is that should a clinical correlation between a
clonotype and clinical events be established, the clono-
typic sequence itself could serve a surrogate marker of
the corresponding unknown antigen. 
In PNH, the results of TCR VB analysis showed
T cell responses involving several immunodominant
clonotypes [23,24,43,47,52]. While identical sequences
have not been found among PNH patients, similarities
of CDR3 motifs have been observed, suggesting a pos-
sible T cell response to common inciting antigens.
Sequences from the immunodominant clonotypes
derived from patients allowed for the design of PCR-
based assays to detect individual clonotypes. The distri-
bution pattern of individual clonotypes established by
this method indicated that imunodominant T cell clono-
typic specificities were shared between the patients and
also found in normal individuals, suggesting that they
are either not related to the primary pathologic process
or that healthy individual have CTL clones recognizing
antigens involved in the autoimmune process leading to
PNH. Recently, several patients with a typical PNH and
significantly expanded expansions of CTL were report-
ed [23,47]. PNH patients described in this study were
subjected to intricate TCR utilization analysis,  previ-
ously unknown LGL-like expansions were found in
these patients suggestive of the CTL mediated immune
process likely directed against hematopoietic progenitor
cells. 
Future potential of clonotypic diagnostics 
Efficient identification or marker clonotypes may
enable introduction of a novel class of diagnostic tools
based on molecular methods. Such a strategy would
have to be individualized due to the diverse HLA back-
ground and patient-specific antigenic recognition spec-
trum. Theoretically, clonotypic arrays can be designed
to enable testing of large numbers disease-specific
clonotypes and clonotypic utilization patterns. Such
technologies may have a broad diagnostic utility. Poten-
tially, such arrays could be HLA-independent as a large
number of clonotypes could be printed that were identi-
fied in the context of many HLA-backgrounds. Finally,
recognition of clonotypes and corresponding antigens
may allow for the generation of predictions algorithms
based on the principle of reverse genetics. Using such
algorithms the sequence of antigenic peptides could be
extrapolated possibly allowing for antigen identifica-
tion. In specific application to immune-mediated bone
marrow failure states, further refinement of the molecu-
lar analysis of TCR repertoire may lead to the identifi-
cation of antigens that drive the CTL response directed
against hematopoietic progenitor and stem cells. 
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